NICE guidance on necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer.
National Institute for Health and Care Excellence, Manchester M1 4BT, UK. Electronic address: nwamaka.umeweni@nice.org.uk.
Nwamaka
N
Umeweni
National Institute for Health and Care Excellence, Manchester M1 4BT, UK.
Helen
H
Knight
National Institute for Health and Care Excellence, Manchester M1 4BT, UK.
Gary
G
McVeigh
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000074322:Antineoplastic Agents, Immunological / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality / Q000556:secondary; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality / Q000556:secondary; D003362:Cost-Benefit Analysis; D017277:Drug Approval; D016527:Drug Costs; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality / Q000473:pathology; D017410:Practice Guidelines as Topic; D019057:Quality-Adjusted Life Years; D016896:Treatment Outcome; D006113:United Kingdom
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000074322:Antineoplastic Agents, Immunological; C527969:necitumumab